Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to demonstrate efficacy and safety of Moxonidine in Indian subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Moxonidine | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Systolic blood pressure reduction |
| Measure | Description | Time Frame |
|---|---|---|
| Piggy-back pharmacoeconomic evaluation; Safety and tolerability |
Not provided
Inclusion Criteria:
Hypertension
Exclusion Criteria:
Severe concomitant diseases, CHF, secondary hypertension, severe hypertension, significant hepatic disease, unstable angina
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Global Clinical Director Solvay | Solvay Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Site 1 | Jubillee Hills Hyderabad | India | ||||
| Site 2 |
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C043482 | moxonidine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Mangalore |
| India |
| Site 3 | New Delhi | India |